BACKGROUND: Applying the chronic care model (CCM) for diabetes management helps improve health outcomes and patient care. The CCM was implemented at U.S. Air Force Wilford Hall Medical Center through the Diabetes Outreach Clinic (DOC) in 2006, but its cost-effectiveness in this setting is unknown. METHODS: We constructed a Markov decision model to estimate DOC cost-effectiveness compared with usual care (UC) over a 20-year period. Based on empirical, post-intervention demographic and clinical data, we applied United Kingdom Prospective Diabetes Study risk equations to predict long-term probabilities of developing microvascular or macrovascular complications. Health care system and societal perspectives were considered, discounting costs and benefits at 3% annually. Intervention costs and outcomes were obtained from military data, while other costs, disease progression data, and utilities were drawn from published literature. RESULTS: From a health care system perspective, the DOC cost $45,495 per quality-adjusted life-year (QALY) compared with UC; from a societal perspective, the DOC compared with UC cost $42,051/QALY (when the model started with the uncomplicated diabetes cohort), $61,243/QALY (when starting with the DOC cohort), or $61,813/QALY (when starting with the UC cohort). In one-way sensitivity analyses, results were most sensitive to yearly costs for specialty care visits. In probabilistic sensitivity analysis, the DOC was favored in 51% of model iterations using an acceptability threshold of $50,000/QALY and in 72% at a threshold of $100,000/QALY. CONCLUSIONS: The DOC strategy for diabetes care, performed with the CCM methodology in a military population, appears to be economically reasonable compared with UC.
BACKGROUND: Applying the chronic care model (CCM) for diabetes management helps improve health outcomes and patient care. The CCM was implemented at U.S. Air Force Wilford Hall Medical Center through the Diabetes Outreach Clinic (DOC) in 2006, but its cost-effectiveness in this setting is unknown. METHODS: We constructed a Markov decision model to estimate DOC cost-effectiveness compared with usual care (UC) over a 20-year period. Based on empirical, post-intervention demographic and clinical data, we applied United Kingdom Prospective Diabetes Study risk equations to predict long-term probabilities of developing microvascular or macrovascular complications. Health care system and societal perspectives were considered, discounting costs and benefits at 3% annually. Intervention costs and outcomes were obtained from military data, while other costs, disease progression data, and utilities were drawn from published literature. RESULTS: From a health care system perspective, the DOC cost $45,495 per quality-adjusted life-year (QALY) compared with UC; from a societal perspective, the DOC compared with UC cost $42,051/QALY (when the model started with the uncomplicated diabetes cohort), $61,243/QALY (when starting with the DOC cohort), or $61,813/QALY (when starting with the UC cohort). In one-way sensitivity analyses, results were most sensitive to yearly costs for specialty care visits. In probabilistic sensitivity analysis, the DOC was favored in 51% of model iterations using an acceptability threshold of $50,000/QALY and in 72% at a threshold of $100,000/QALY. CONCLUSIONS: The DOC strategy for diabetes care, performed with the CCM methodology in a military population, appears to be economically reasonable compared with UC.
Authors: Gretchen A Piatt; Robert M Anderson; Maria M Brooks; Thomas Songer; Linda M Siminerio; Mary M Korytkowski; Janice C Zgibor Journal: Diabetes Educ Date: 2010-03-03 Impact factor: 2.140
Authors: Edward J Boyko; Isabel G Jacobson; Besa Smith; Margaret A K Ryan; Tomoko I Hooper; Paul J Amoroso; Gary D Gackstetter; Elizabeth Barrett-Connor; Tyler C Smith Journal: Diabetes Care Date: 2010-05-18 Impact factor: 19.112
Authors: Teresa B Gibson; Todd A Lee; Christine S Vogeli; Julia Hidalgo; Ginger Smith Carls; Katherine Sredl; Susan DesHarnais; William D Marder; Kevin B Weiss; Thomas V Williams; Alexandra E Shields Journal: Mil Med Date: 2009-09 Impact factor: 1.437
Authors: E D Gorham; E Barrett-Connor; R M Highfill-McRoy; S B Mohr; C F Garland; F C Garland; C Ricordi Journal: Diabetologia Date: 2009-07-24 Impact factor: 10.122
Authors: Rachel L Randell; Millie D Long; Christopher F Martin; Robert S Sandler; Wenli Chen; Kristen Anton; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: Teryl K Nuckols; Emmett Keeler; Laura J Anderson; Jonas Green; Sally C Morton; Brian J Doyle; Kanaka Shetty; Aziza Arifkhanova; Marika Booth; Roberta Shanman; Paul Shekelle Journal: Diabetes Care Date: 2018-05 Impact factor: 17.152
Authors: Gerardine Doyle; Shane O'Donnell; Etáin Quigley; Kate Cullen; Sarah Gibney; Diane Levin-Zamir; Kristin Ganahl; Gabriele Müller; Ingrid Muller; Helle Terkildsen Maindal; Wushou Peter Chang; Stephan Van Den Broucke Journal: BMJ Open Date: 2017-06-04 Impact factor: 2.692
Authors: Kevin I Duan; Francisco Rodriguez Garza; Hugo Flores; Daniel Palazuelos; Jimena Maza; Luis Alberto Martinez-Juarez; Patrick F Elliott; Elena Moreno Lázaro; Natán Enriquez Rios; Gustavo Nigenda; Lindsay Palazuelos; Ryan K McBain Journal: BMJ Open Date: 2021-04-07 Impact factor: 2.692